Clinical Trial Update: A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

View source ↗

Summary

A completed Canadian clinical trial assessing the safety of Humate-P with reduced infusion volume in Von Willebrand Disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Von Willebrand Disease

Drugs mentioned

• Humate-P (Antihemophilic Factor/Von Willebrand Factor Complex)

Snippet

Sponsor: CSL Behring | Conditions: Von Willebrand Disease | Status: COMPLETED